The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer.
 
Luke T. Nordquist
No Relationships to Disclose
 
Neal D. Shore
Leadership - Large Urology Group Practice Association
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Sanofi; Tolmar
 
James J. Elist
Stock and Other Ownership Interests - Panacea Pharmaceuticals
 
Jamie C. Oliver
Employment - Accelovance
Leadership - Accelovance
 
William Gannon
Employment - CCTC
Leadership - CCTC
Consulting or Advisory Role - CCTC
 
Amir H. Shahlaee
Employment - Panacea Pharmaceuticals
Stock and Other Ownership Interests - Panacea Pharmaceuticals
Consulting or Advisory Role - Accelovance; Amarex
Speakers' Bureau - Pfizer
Research Funding - Newlink Genetics
Travel, Accommodations, Expenses - Panacea Pharmaceuticals
 
Steven A. Fuller
Employment - Panacea Pharmaceuticals
Leadership - Panacea Pharmaceuticals
Stock and Other Ownership Interests - Panacea Pharmaceuticals
 
Hossein A. Ghanbari
Employment - Panacea Pharmaceuticals
Leadership - Panacea Pharmaceuticals
Stock and Other Ownership Interests - Panacea Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Panacea Pharmaceuticals